Free tool
FAERS Monitor: Rezlidhia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215814 or its brand name (Rezlidhia, Olutasidenib). Reports on generic versions are filed under their own applications.
Reports
289
Serious
164
57% of reports
Hospitalization
114
Death reported
45
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use75
- hospitalisation43
- death40
- fatigue27
- nausea27
- product dose omission issue25
- product prescribing issue23
- constipation17
- transfusion13
- pneumonia11
- drug ineffective10
- dyspnoea10
- disease progression9
- vomiting9
- abdominal discomfort8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 41 |
| 2024 | 91 |
| 2025 | 111 |
| 2026 | 46 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,870 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| transfusionSignal | 13 | 90.4 | 53.1 | 1,061 |
| product prescribing issueSignal | 23 | 76.9 | 52.0 | 1,648 |
| hospitalisationSignal | 43 | 20.4 | 15.5 | 778 |
| off label useSignal | 75 | 6.2 | 5.1 | 338 |
| product dose omission issueSignal | 25 | 6.2 | 4.3 | 105 |
| constipationSignal | 17 | 5.7 | 3.6 | 61 |
| disease progressionSignal | 9 | 5.5 | 2.9 | 29 |
| abdominal discomfortSignal | 8 | 3.5 | 1.8 | 12 |
| deathSignal | 40 | 3.4 | 2.5 | 67 |
| fatigueSignal | 27 | 2.5 | 1.8 | 24 |
| nauseaSignal | 27 | 2.5 | 1.7 | 23 |
| pneumoniaSignal | 11 | 2.5 | 1.4 | 8 |
| vomiting | 9 | 1.4 | 0.7 | 1 |
| dyspnoea | 10 | 1.3 | 0.7 | 0 |
| drug ineffective | 10 | 0.6 | 0.3 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.